Vyome Holdings, Inc. HIND
1.57 USD +0.03 (+1.95%)
At closeNov 11, 2026, 4:00 PM EST
1.55 -0.02 -1.27%
After hours · Nov 11, 4:00 PM ET
1.53 Day range 1.72
1.53 52-week range 5.88
- YTD
- -54.36%
- 1 year
- -70.43%
News
businesswire.com Vyome Co-Founder Dr. Shiladitya Sengupta Promoted to Professor at Harvard Medical School CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND) ("Vyome"), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions,…
businesswire.com Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND #ocularinflammation--Vyome Holdings, Inc. (Nasdaq: HIND) (“Vyome”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare…
benzinga.com Vyome Holdings' ReShape Lifesciences Has Received A Notice Of Allowance For A U.S. Patent Titled "VAGUS NERVE NEUROMODULATION FOR THE TREATMENT OF THE HYPOGLYCEMIC STATE". https://patentcenter.uspto.gov/applications/18702356/ifw/docs
benzinga.com Vyome Holdings Appoints Jerry Leonard As CFO, Succeeding Robert Dickey IV, Who Served As Interim CFO Since August 2025 Finance executive with more than 25 years of experience brings extensive expertise in public company financial management, SEC reporting, financial operations, and governanceVyome Holdings, Inc.…
businesswire.com Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND #CFO--Vyome Holdings, Inc. (Nasdaq: HIND) (“Vyome” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated…
benzinga.com Chardan Capital Initiates Coverage On Vyome Holdings with Buy Rating, Announces Price Target of $3.5 Chardan Capital analyst Keay Nakae initiates coverage on Vyome Holdings (NASDAQ:HIND) with a Buy rating and announces Price Target of $3.5.
benzinga.com Vyome Appoints Jerry Leonard As CFO On August 27, 2026 On August 27, 2026, the board of directors (the "Board") of Vyome Holdings, Inc. (the "Company") appointed Jerry Leonard as the Company’s Chief Financial Officer. In connection with Mr. Leonard’s
businesswire.com Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND, “Vyome”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings…- benzinga.com China National Intellectual Property Administration Grants Vyome Patent Chinese Patent No. ZL 2021 1 0758695.X Newly granted Chinese patent broadens Vyome's intellectual property estate with additional formulation and therapeutic use claims for besifloxacin gel in inflammatory acne, supporting future…
businesswire.com Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND #VT1953--Vyome Holdings, Inc. (NASDAQ: HIND) (“Vyome” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated…
gurufocus.com Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet Vyome Holdings, Inc. (Nasdaq: HIND)(âVyomeâ), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today
businesswire.com Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (Nasdaq: HIND)(“Vyome”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today reports…
businesswire.com Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND) today announced the signing of an agreement with Impetis Biosciences Limited (“Impetis”), a TATA Enterprise, that…- benzinga.com Vyome Holdings Reports Data On Its Phase 2 Investigator Initiated Trial Results, Preclinical Data Of VT-1953 To Treat Symptoms Of Malignant Fungating Wounds At American Association For Cancer Research Annual Meeting Vyome Holdings, Inc. ("Vyome") (Nasdaq: HIND) presented its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential…
businesswire.com Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026.
benzinga.com Vyome Holdings To Present Full Phase 2 Investigator Initiated Study Results And Preclinical Data Supporting Efficacy And Safety Of VT-1953 As Potential Treatment For Malodor And Other Symptoms Of MFW At 2026 AACR Complete Phase 2 clinical data on the efficacy and safety of VT-1953 in MFW patients accepted for presentation at the annual meeting of the American Association for Cancer ResearchVyome Holdings,…
businesswire.com Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND) today announced that the company will present its full Phase 2 investigator initiated study results and preclinical…- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
businesswire.com Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase.
businesswire.com Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome announces the publication of positive preclinical results in uveitis, addressing a $3B potential market opportunity.
benzinga.com Vyome Files For Orphan Drug Status For VT-1953, Its Lead Clinical Program Acceptance of Orphan Drug Status would confer certain anticipated US Market Exclusivity, R&D tax benefits, and PDUFA fee waiver of approximately $3MIndependent third-party assessment estimates a…
businesswire.com Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare…- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
businesswire.com Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Vyome Shares Move Higher; Co Highlights Independent Analyst Valuation Of Vyome Third-party analysis estimates the total addressable U.S. market to be approximately USD 2.2 billionModeled peak annual U.S. sales approaching USD 600 million for VT-1953Independent valuation…
businesswire.com Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study CAMBRIDGE, Mass.--(BUSINESS WIRE)--Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session 
defenseworld.net Vyome (NASDAQ:HIND) versus Medline (NASDAQ:MDLN) Critical Review Medline (NASDAQ: MDLN - Get Free Report) and Vyome (NASDAQ: HIND - Get Free Report) are both manufacturing companies, but which is the better business? We will contrast the two businesses based on…
defenseworld.net Vyome (NASDAQ:HIND) & Medline (NASDAQ:MDLN) Critical Analysis Vyome (NASDAQ: HIND - Get Free Report) and Medline (NASDAQ: MDLN - Get Free Report) are both manufacturing companies, but which is the superior investment? We will compare the two businesses based on…- benzinga.com Vyome Holdings' Subsidiary LiveChain Enters Binding LOI To Acquire Humanyze Convertible Note In Equity Exchange with Remus Capital Entry into a Material Definitive Agreement Letter of Intent with LICH and Remus: On December 17, 2025, Vyome Holdings, Inc. (the "Company") entered into a binding letter of intent (the "LOI") among,…
businesswire.com Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company CAMBRIDGE, Mass.--(BUSINESS WIRE)--LICH LOI with Remus.- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
defenseworld.net Analyzing Profusa (NASDAQ:PFSA) & Vyome (NASDAQ:HIND) Vyome (NASDAQ: HIND - Get Free Report) and Profusa (NASDAQ: PFSA - Get Free Report) are both small-cap manufacturing companies, but which is the superior stock? We will compare the two companies…
defenseworld.net Critical Survey: Perspective Therapeutics (NASDAQ:CATX) & Vyome (NASDAQ:HIND) Vyome (NASDAQ: HIND - Get Free Report) and Perspective Therapeutics (NASDAQ: CATX - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will compare…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Vyome's VT-1953 Announces Phase 2 Efficacy In Malignant Fungating Wounds, Paving Path To Pivotal Trial VT-1953 treatment over 14 days resulted in highly statistically significant improvements in bad smell or malodor associated with malignant fungating wound (primary endpoint) (P =…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Vyome Acquires Oculo, An AI Startup Launched At The Massachusetts Institute Of Technology And Launched A New Business Unit Focused On Using AI To Tackle Inflammation; Deal Terms Were Undisclosed This new business unit will leverage Oculo's assets to develop an AI psychiatrist trained on data from both the US and India, and will be overseen by a newly-formed Vyome Board of Directors AI…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Market-Moving News for September 17th SPRC: 268% | SciSparc shares are trading higher after Automax Motors filed a motion to Jerusalem District Court in connection with its merger with the company. HIND: 199% | Vyome Unveils Preclinical…
- benzinga.com Vyome Unveils Preclinical Data For VT-1908 Eye Drops To Treat Uveitis, A Leading Cause Of Blindness Vyome Holdings, Inc. (NASDAQ:HIND), a clinical-stage healthcare holding company, presented results from its preclinical studies investigating VT-1908 (the first topical formulation of mycophenolate)…
benzinga.com Deal Dispatch: Musk-Altman Drama, Ashton Kutcher SoHo House Play And We Pose Questions To Private Equity Pros Elon's OpenAI bid flops, Vyome reviews Livechain, Peraso courts acquirers, GTCR faces antitrust and pizza chains go bankrupt.- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Empery Digital, Riskified And Other Big Stocks Moving Lower In Monday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session